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Abstract
Background: Improved understanding of prostate cancer radiobiology combined with advances in delivery of
radiation to the moving prostate offer the potential to reduce treatment-related morbidity and maintain quality of
life (QOL) following prostate cancer treatment. We present preliminary results following stereotactic body
radiotherapy (SBRT) treatment for organ-confined prostate cancer.
Methods: SBRT was performed on 304 patients with clinically localized prostate cancer: 50 received 5 fractions of 7
Gy (total dose 35 Gy) and 254 received 5 fractions of 7.25 Gy (total dose 36.25 Gy). Acute and late toxicity was
assessed using the Radiation Therapy Oncology Group scale. The Expanded Prostate Cancer Index Composite
questionnaire was used to assess QOL. Prostate-specific antigen response was monitored.
Results: At a median 30-month (26 - 37 month, range) follow-up there were no biochemical failures for the 35-Gy
dose level. Acute Grade II urinary and rectal toxicities occurred in 4% of patients with no higher Grade acute
toxicities. One Grade II late urinary toxicity occurred with no other Grade II or higher late toxicities. At a median 17-
month (8 - 27 month, range) follow-up the 36.25 Gy dose level had 2 low- and 2 high-risk patients fail
biochemically (biopsy showed 2 low- and 1 high-risk patients were disease-free in the gland). Acute Grade II
urinary and rectal toxicities occurred in 4.7% (12/253) and 3.6% (9/253) of patients, respectively. For those patients
with a minimum of 12 months follow-up, 5.8% (12/206) had late Grade II urinary toxicity and 2.9% (6/206) had late
Grade II rectal toxicities. One late Grade III urinary toxicity occurred; no Grade IV toxicities occurred. For both dose
levels at 17 months, bowel and urinary QOL returned to baseline values; sexual QOL decreased by 10%.
Conclusions: The low toxicity and maintained QOL are highly encouraging. Additional follow-up is needed to
determine long-term biochemical control and maintenance of low toxicity and QOL.
Background
Conventional treatments for localized prostate cancer
target local control at the potential expense of morbidity
and decreased quality of life. Urinary function impair-
ment has been reported to occur in 5-28% of patients at
2 years after radical prostatectomy (RP) and in 2-14% of
patients at 2 years after external beam radiation therapy
(EBRT) [1,2]. Bowel distress is reported in 3 - 21% of
RP and 8 - 37% of EBRT patients 2 years after treatment
[2]. Erectile dysfunction has been reported at rates of
51-82% and 30-51% two-years following RP and EBRT,
respectively [2-4]. Sexual quality of life estimates show
similar results for these treatments [1]. Indeed, the rate
of such complications, and the extent to which they
reduce the quality of life of prostate cancer patients,
contributed to a recent recommendation from the Uni-
ted States Preventive Services Task Force (USPTF)
against routine prostate-specific antigen (PSA) screening
for prostate cancer in men aged 75 or older [5].
Advances in targeted radiation delivery and a modern
understanding of the radiobiology of prostate cancer
suggest approaches to controlling prostate cancer while
decreasing treatment-related toxicity. Radiobiologically,
slowly proliferating prostate cancer cells are thought to
have a low a/b ratio; a recent review of 17 studies esti-
mated an average a/b ratio of 1.85 Gy [6]. This low a/b
ratio suggests that prostate cancer has high sensitivity to
dose per fraction, which suggests that a hypofractionated
radiation delivery regimen, with a large radiation dose
delivered in a smaller number of fractions, may be
advantageous.
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treatments for prostate cancer occurred in the early
1960’s [7]. These treatments, delivering 6 fractions of 6
Gy to a total dose of 36 Gy, were motivated by resource
limitations rather than radiobiology. Nevertheless, two
decades of follow-up has confirmed that this regimen
led to favorable local response, survival, and safety over
the long term. Subsequently, hypofractionated prostate
cancer treatment has been performed with EBRT in per-
fraction doses ranging from 2.5 - 3.1 Gy [8-11], with
brachytherapy (BT) in per-fraction doses of 5.5 - 11.5
Gy[12,13], and with linac-based stereotactic body radio-
therapy (SBRT) using 5 fractions of 6.7 Gy [14]. In a
recent paper King et al. reported a median 33-month
follow-up for patients that received 5 fractions of 7.25
Gy (total dose 36.25 Gy). They reported no biochemical
failure with early and late toxicity profiles no worse than
conventional EBRT [15]. Thus, in relatively short-term
follow-up, hypofractionated treatment of prostate cancer
can result in effective biochemical control while main-
taining low rectal and bladder toxicities.
Technological advances have allowed precise targeting
and delivery of radiation to the moving prostate while
sparing normal tissues. Thiss u g g e s t st h ep o t e n t i a lt o
reduce treatment-related morbidity and maintain quality
of life following prostate cancer treatment. In this
report, we present preliminary biochemical control
results on the treatment of 304 low-, intermediate-, and
high-risk prostate cancer patients using SBRT, with par-
ticular attention to urinary, rectal and sexual toxicities
and their corresponding impact on patient quality of life.
Methods
Patient population
Data were prospectively collected for all clinically loca-
lized prostate cancer patients that were treated with
SBRT at Winthrop University Hospital in Mineola, NY
between April 2006 and July 2008. The 304 patients all
had adenocarcinoma of the prostate; 280 (92.2%)
patients presented with clinical stage T1cN0 M0 and 24
(7.8%) patients presented with clinical stage T2aN0 M0
as determined by physical exam, bone scan and CT
scans. The median PSA at presentation was 5.8 ng/ml
(range 0.7 - 27.3 ng/ml). Table 1 details the patient
characteristics. All patients signed consent statements
and were informed of the potential risks involved with
this treatment. Institutional IRB-approval was obtained
on the treatment protocol.
Hormone therapy
Fifty-seven patients received neoadjuvant hormonal
therapy. Of those patients, 29(51%) received hormone
therapy for three months or less as it was generally
stopped at the time of consultation. The remaining 28
patients (49%) received hormone therapy for up to one
year at the discretion of the patient’s urologist.
Treatment planning and delivery
Image-guided SBRT was delivered to all patients using
the CyberKnife (Accuray Inc., Sunnyvale, CA) with Mul-
tiplan inverse treatment planning and motion tracking
of internal fiducial seeds. A detailed description of the
CyberKnife system can be found elsewhere [16].
Approximately two weeks before treatment planning,
four fiducial seeds were placed transperineally in each
patient to allow for motion tracking during treatment.
The implanted seeds were positioned with two at the
prostate apex and two at the base. After allowing time for
possible seed migration, treatment planning was per-
formed prior to the treatment day using a CT scan (1.5-
mm cuts), with MRI fusion where feasible. All pretreat-
ment imaging was performed with the patient in the
same position used for treatment delivery. For low-risk
patients, the prostate alone was the gross target volume
(GTV). For intermediate- to high-risk patients, the proxi-
mal half of the seminal vesicles was added to the GTV if
the Gleason Score > 6 and the PSA > 15 ng/ml. Following
delineation of the GTV, a margin was added to create the
planning target volume (PTV). For low- and intermedi-
ate-risk patients, the margin was 5 mm throughout
except posteriorly by the rectum where a 3-mm margin
was used. For high-risk patients, an 8-mm margin was
added on the involved side. All patients had the bladder,
prostate, rectum, seminal vesicles and penile bulb con-
toured, but the urethra was not identified.
SBRT was delivered at two dose levels. The first 50
treated patients (16%) received a total dose of 35 Gy in 5
fractions of 7 Gy to cover at least 96% of the PTV. The
subsequent 254 patients (84%) received a total dose of
36.25 Gy in 5 fractions of 7.25 Gy to cover at least 96% of
the PTV. The dose was increased when researchers
reported [17] using a higher dose with acceptable toxi-
city. The mean number of beams was 152 (range 140 -
170). The mean D50 to the bladder and rectum was 43%
and 41% of the prescribed dose, respectively. Figure 1
presents a representative dose volume histogram.
Treatments were performed on five consecutive days.
The morning of each treatment patients had a bowel
prep including Dulcolax® (Boehringer Ingelheim, Ger-
many) and a Fleet Enema. In addition, at least 15 - 20
minutes before treatment all patients received 1500 mg
of amifostine (MedImmune, LLC Gaithersburg, MD)
mixed in saline instilled into the rectum.
Follow-up schedule and toxicity assessment
All patients were seen for follow-up three weeks after
final treatment, again four months later, and every six
months thereafter. Toxicity was assessed at every
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Index Composite (EPIC) questionnaire [18] and the
Radiation Therapy Oncology Group (RTOG) urinary
and rectal toxicity scale [19]. Acute toxicity was defined
as those events that presented and resolved within the
first 5 months following treatment. PSA was assessed by
the referring urologist 6 months after treatment and
every 6 months thereafter. Biochemical failure was the
end point of the study, using the Phoenix (nadir + 2)
biochemical failure definition [20].
Results
Follow-up
The median follow-up for patients receiving the lower
dose (35 Gy) was 30 months (range 26 - 37 months).
The median follow-up for patients receiving the higher
dose (36.25 Gy) was 17 months (range 8 - 27 months).
Three patients in the 35-Gy dose level died and three in
the 36.25-Gy dose level died, none of prostate cancer.
Toxicity
The 5-month toxicity follow-up has occurred for all
patients except one who died from causes other than
prostate cancer at 4 months. Thus, we have acute toxi-
city profiles for 303 patients. Table 2 presents these
acute urinary and rectal toxicities on the RTOG scale
broken down by treatment dose. No patients experi-
enced any Grade III or IV acute complications. Less
than 5% of patients (14/303) experienced any acute
Grade II urinary or rectal toxicity.
Table 1 Patient characteristics at diagnosis.
Age at diagnosis Years
Mean (range) 69.2 (45 - 88)
Age at diagnosis Number of Patients Percent of Patients
45-49 1 0.3
50-54 7 2.3
55-59 23 7.6
60-64 35 11.5
65-70 54 17.8
70-74 80 26.3
75-79 54 17.8
80-84 36 11.8
85-88 14 4.6
PSA level at diagnosis ng/mL
Mean (range) 6.08 (0.7 to 27.7)
Median 5.8
PSA level at diagnosis Number of Patients Percent of Patients
<4 ng/mL 59 19.4
4-10 ng/mL 203 66.8
>10-20 ng/mL 40 13.2
>20 ng/mL 2 0.7
Clinical Stage Number of Patients Percent of Patients
T1cN0 M0 280 92.1
T2aN0 M0 24 7.9
Gleason Score Number of Patients Percent of Patients
= 6 222 73
= 7 70 23
> 8 12 4
Hormone Treatment Number of Patients Percent of Patients
No 247 81.3
Yes 57 18.8
Risk Assessment: Criteria Number of Patients Percent of Patients
Low Risk: Gleason Score ≤ 6 and PSA ≤ 10 ng/ml. 211 69.4
Intermediate Risk: Gleason = 7 or PSA>10 and PSA < 20 81 26.6
High Risk: Gleason ≥ 8 or PSA > 20 12 3.9
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ken down by dose for those patients with a minimum
follow-up of 12 months. For the 35-Gy dose level, 2
patients died before their 12-month follow-up. Thus,
while follow-up for all other patients extends to 26
months the late toxicity results only include 48 patients.
For the 36.25-Gy dose level, 2 patients died before their
12-month follow-up and 46 patients have not yet
reached their 12-month follow-up. Late urinary Grade II
complications were observed in 5.1% of patients (13/
256) and late rectal Grade II complications were
observed in 2.3% of patients (6/256). One late Grade III
urinary toxicity occurred in the 36.25 Gy dose level. No
significant differences in complication rates were
observed for patients receiving the 35 Gy or 36.25 Gy
doses.
Quality of life
All patients completed the initial EPIC questionnaire
prior to treatment. For subsequent time points the num-
ber of patients varied depending on the number that
reached each follow-up time point and the number that
completed the questionnaires. Figure 2 shows the EPIC
scores for bowel, urinary and sexual quality of life
(QOL) along with patient response rates. Bowel and
urinary QOL scores decreased initially before returning
to baseline values. For sexual QOL, an overall decrease
of 10% in the QOL score was observed. To further
examine sexual QOL, we verbally screened patients that
were potent prior to treatment (n = 228) to determine if
they remained potent. At a median 18 months follow-up
(range 7-37 months) 87% percent (198/228) stated they
Figure 1 Dose volume histogram for PTV, bladder and rectum.
Table 2 Acute bladder/rectal toxicity using RTOG scoring
after prostate treatment using the 35 and 36.25 Gy
doses.
RTOG grade % (number) of patients
Total
Dose
0 I II III & IV
Acute
Urinary
35 Gy 24% (12) 72% (36) 4% (2) -
36.25 Gy 20.2%
(51)
75.1%
(190)
4.7% (12) -
Acute Rectal 35.00 Gy 20% (10) 76% (38) 4% (2) -
36.25 Gy 21.7%
(55)
74.7%
(189)
3.6% (9) -
Table 3 Late bladder/rectal toxicity using RTOG scoring
after prostate treatment using the 35 and 36.25 Gy
doses for those patients with a minimum 12 month
follow-up
RTOG grade % (number) of patients
Total
Dose
0 I II III IV
Late
Urinary
35 Gy 94% (45) 4% (2) 2% (1) - -
36.25 Gy 88.9%
(183)
4.8%
(10)
5.8%
(12)
0.5% (1) -
Late Rectal 35 Gy 95.8% (46) 4.2% (2) - - -
36.25 Gy 91.8%
(189)
5.3%
(11)
2.9% (6) - -
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function medication.
Biochemical control, PSA response and PSA nadir
As with late toxicity, we have limited our PSA analysis
to those patients with a minimum 12-month follow-up.
In addition, we have excluded the patients who received
ADT treatment. The mean PSA decreased after treat-
ment as shown in Figure 3 which presents the PSA
response for the two different dose levels. We note that
the number of patients for which PSA is available at
each time point varied depending on the number that
reached each follow-up time point and the number that
completed their PSA blood work. Table 4 presents the
number of patients achieving the specified PSA nadir
thresholds over time.
T w ol o w - r i s ka n dt w oh i g h - r i s kp a t i e n t s ,a l lt r e a t e d
with the higher dose, failed biochemically. None of the
intermediate-risk patients failed biochemically. The two
low-risk patients that failed biochemically were both
Figure 2 EPIC Quality of Life scores over time for bowel, urinary and sexual function. All patients initially completed the EPIC
questionnaire, at 3 weeks 264 of 304 (86.84%) patients responded, at 5 months 203 of 304 (66.78%) responded, at 11 months 175 of 272
(64.34%) responded, and at 17 months 145 of 192 (75.53%) responded. Error bars represent 95% confidence intervals. Higher scores represent a
better quality of life.
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One of the two high-risk patients that failed was biopsy
proven to be recurrent in the gland with 4 out of the 12
cores showing a Gleason Score of 10. A PSA bounce
(defined as an increased PSA > 0.2 ng/mL followed by a
decreased PSA to previous value or lower) occurred in
16% (37/237 of the patients at a median of 18 months.
The median bounce was 0.35 ng/ml (range 0.2 - 1.08
ng/ml).
Discussion
Acute toxicity
A variety of RTOG graded toxicity rates have been
reported for both conventionally fractionated EBRT and
intensity modulated radiation therapy (IMRT) treatment
of prostate cancer. Michalski et al. and Peeters et al.
examined delivery of 78 Gy in 2-Gy fractions with
reported rates of 36-41% for Grade II and 4-14% for
Grade III acute urinary toxicity [21,22]. For acute rectal
toxicity, Peeters et al. reported 44% Grade II and 5%
Grade III toxicity [22]. Bechendorf et al. applied a dose
of 80 Gy in 2-Gy fractions with 31% Grade II and 5%
Grade III acute urinary toxicity; acute rectal toxicity
rates were 29% for Grade II and 2% for Grade III [23].
Zietman et al. applied a dose of 79.2 Gy using a combi-
nation of EBRT and protons with 49% Grade II, 1%
Grade III, and 1% Grade IV acute urinary toxicity; acute
G r a d eI Ir e c t a lt o x i c i t yw a s5 7 % .I nas t u d yo fI M R Ti n
which 81-85 Gy were delivered in 1.8-Gy fractions, 28%
G r a d eI Ia n d0 . 1 %G r a d eI I Ia c u t eu r i n a r yt o x i c i t yw a s
reported; acute Grade II rectal toxicity was 4.5%. In
comparison, assuming an a/b =1 . 5G y ,o u rd o s er e g i -
mens equal approximately 91 Gy and 96 Gy, respec-
tively, at 1.8 Gy per fraction. Thus, although our
therapeutic doses were higher than the above studies
our observed rate of acute urinary and rectal toxicity
w a sl o w e r ,w i t hl e s st h a n5 %o fp a t i e n t se x p e r i e n c i n g
any acute Grade II urinary or rectal toxicity and none
experiencing any higher grade acute toxicity.
Late toxicity
Our results to date for hypofractionated SBRT of loca-
lized prostate cancer when administered with rectal ami-
fostine also indicate less late toxicity than that
previously published for hypofractionated SBRT and
conventionally fractionated EBRT. King et al. treated 41
patients with SBRT to a total dose of 36.25 Gy in 5 frac-
tions of 7.25 Gy [15]. At a median 33-month follow-up
they reported late Grade II urinary toxicity in 24% of
patients whereas we observed 2% Grade II urinary toxi-
city at 30 months follow-up for the 35 Gy dose level. At
17 months median follow-up for the 36.25 Gy dose level
we observed 5.8% Grade II late urinary toxicity and one
late Grade III urinary toxicity. As discussed by King et
al. these late urinary toxicities may increase over time,
therefore, the durability of our observed late urinary
toxicity requires additional follow-up.
For late bowel toxicity, King et al. observed 15% Grade
II toxicity at a median 33-month follow-up [15]. An
EBRT dose-escalation trial [24] in which 78 Gy was
delivered in 2-Gy fractions obtained similar late rectal
toxicities, with 19% and 7% of patients observing Grade
II and Grade III toxicities, respectively, at a median fol-
low-up of 7 years. Similar results have also been
reported for EBRT + protons by Zietman et al. [25] with
delivery of either 70.2 Gy or 79.2 Gy at a median follow-
up of 5.5 years. Our observed bowel toxicity rate at a
median 30-month follow-up for the 35 Gy dose level is
4.2% (2/48) for Grade I toxicities with no higher grade
toxicities. Rectally administered amifostine prior to
EBRT for prostate cancer has resulted in a significant
decrease in RTOG Grade II toxicity incidence [26].
Thus, we attribute our low bowel toxicity rate to rectal
administration of amifostine prior to delivery of each
treatment fraction. Rectal administration of amifostine is
easy to perform and has no related toxicity in compari-
son to intravenous administration [26,27].
The MD Anderson results show that the rate of toxi-
city for EBRT treatment continued to increase during
the first 5 years following treatment before hitting a pla-
teau [24]. However, other studies have shown late rectal
toxicity to occur less frequently as time progresses with
comparable toxicity-free survival at 3 versus 5 years
[25,28]. Thus, while our rectal toxicity rates may
Table 4 Percent of patients who did not receive hormone
therapy with at least 12 months follow-up achieving
specified PSA nadir threshold over time.
Percent (Number) of patients achieving specified PSA
nadir
35 Gy 6 months
(40
patients)
12 months
(38
patients)
18
months
(28
patients)
24
months
(43
patients)
30
months
(32
patients)
< 1 ng/
mL
48% (19) 55% (21) 57% (16) 88% (38) 88% (28)
< .5 ng/
mL
15% (6) 37% (14) 46% (13) 65% (28) 75% (24)
36.25 Gy 6 months
(148
patients)
12 months
(133
patients)
18
months
(43
patients)
24
months
(21
patients)
< 1 ng/
mL
35% (53) 45% (60) 76% (33) 81% (17)
< .5 ng/
mL
19% (29) 26% (34) 51% (22) 66% (14)
A chi-square test of independence was performed between the 35 Gy and
36.25 Gy. For both the < 1 ng/ml (c2 = 5.794, p = .122) and < .5 ng/ml (c2=
2.259, p = .520) cases the chi-square test shows no significant difference is
present between 35 Gy and 36.25 Gy.
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observed to date is highly encouraging.
Quality of life
In a large study of QOL, Sanda et al. compared QOL in
patients treated with RP (n = 603), EBRT (n = 292) and
low-dose rate BT (n = 306) using, among other measures,
EPIC scores [1]. Comparison of these results at 24
months to the current studies SBRT results at 17 months
suggests that our hypofractionated SBRT approach
resulted in an overall similar or potentially better QOL to
these other treatment modalities. In the case of the bowel
QOL, the Sanda et al. study shows an approximate 10%
decrease in EPIC QOL for both EBRT and BT. Our
results show a return to pre-treatment QOL that matches
those observed for RP, suggesting an improved QOL for
SBRT over both EBRT and BT for the bowel. In the case
of urinary QOL, the Sanda et al. results show a near
return to baseline EPIC values for EBRT and BT, but a
significant loss of QOL for prostatectomy [1].
Although our baseline urinar ys c o r ei ss l i g h t l yl o w e r
than those in the Sanda et al. study (86.5% versus approxi-
mately 93%), we observed a similar overall recovery to
baseline values that exceeded those observed for RT and
Figure 3 Median PSA levels (ng/ml +/- 1 standard deviation) for patients who did not receive ADT and who have a minimum follow-
up of 12 month in the (A) 35 Gy dose level and (B) 36.25 Gy dose level.
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the SBRT results observed by King et al. [15]. Lastly, for
sexual QOL our results parallel those of RT and BT, show-
ing about a 10% decrease in sexual QOL. Prostatectomy,
which had a higher initial baseline, shows an overall signif-
icantly worse sexual QOL at 2 years.
The current study reports EPIC results at the 17-
month follow-up, with 75% (145/192) of patients com-
pleting the EPIC questionnaires (i.e., responses at 17
months are available for 48% of all patients). The com-
parisons to the Sanda et al. study are based on their
EPIC scores at 24 months. Examination of the Sanda
results show that, in general, EPIC QOL scores plateau
or increase only slightly between the 12-month and 2-
year follow-up. Our results show no significant differ-
ence between the 11- and 17-month EPIC QOL;
whether EPIC QOL at the 2-year follow-up will remain
stable will require continued follow-up.
PSA response & biochemical control
At a median 30-month follow-up for patients treated
with 35 Gy, the reduction in PSA values is very similar to
that reported by King et al. [15]. In addition, we observed
a similar overall PSA response for patients with a mini-
mum 12-month follow-up independent of overall treat-
ment dose (Figure 3 and Table 4). Although encouraging,
it should be noted that a recent commentary by King et
al. identified the potential for some beams in CyberKnife
prostate treatments to pass through the testicles [29]. We
examined 12 patients’ treatment plans and found the
median D50 testicular dose was 5.28 Gy (range, 3.2 - 11.8
Gy, see Figure 4). King et al. noted that some studies sug-
gest hypogonadism and altered PSA values can occur at
doses as low as 2-4 Gy following conformal radiation
treatments [30,31]. In contrast, a study of IMRT treat-
ment for prostate cancer found mean doses of 5.4 and
5.1 Gy to the right and left testicles did not significantly
alter either testosterone levels or PSA levels [32]. We
have not observed any clinical evidence of hypogonadism
in any patients. While we acknowledge the testicular
dose could alter serum testosterone and PSA values, our
results suggest that this did not happen in the current
study. Nevertheless, we examine all our treatment plans
carefully, and attempt to exclude beams that transit the
Figure 4 Representative sagittal view of a treatment plan illustrating dose to testes.
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ment plan. We will also assay testosterone levels as part
of our ongoing follow-up.
Conclusions
Our results show that SBRT of early stage prostate can-
cer with rectal administration of amifostine can be per-
formed with low acute toxicity. At a median 30-month
follow-up for the 35 Gy dose level, the long-term urin-
ary and rectal toxicity are both low. EPIC QOL ques-
tionnaires also suggest that urinary, rectal and sexual
QOL following SBRT may be comparable, if not better
than that for EBRT, BT and RP. Furthermore, at our
facility SBRT is less costly (by roughly $15,000US) than
IMRT while being much less inconvenient for the
patient than a 45-day course of IMRT. Longer term fol-
low-up and additional studies are needed to confirm the
durability of biochemical control, toxicity and QOL with
SBRT of prostate cancer.
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